GlaxoSmithKline's seasonal mRNA influenza vaccine met Phase 2 trial success criteria and advances to Phase 3.

GlaxoSmithKline (GSK) announced promising results from a Phase 2 trial of its seasonal mRNA influenza vaccine, which effectively elicited immune responses against both influenza A and B strains in various age groups. Meeting all predefined success criteria, the vaccine is set to advance to Phase 3 clinical development. This initiative aligns with GSK's strategy to enhance its vaccine portfolio amid declining revenues from existing medications.

September 12, 2024
17 Articles

Further Reading